JPS6232728B2 - - Google Patents
Info
- Publication number
- JPS6232728B2 JPS6232728B2 JP7309681A JP7309681A JPS6232728B2 JP S6232728 B2 JPS6232728 B2 JP S6232728B2 JP 7309681 A JP7309681 A JP 7309681A JP 7309681 A JP7309681 A JP 7309681A JP S6232728 B2 JPS6232728 B2 JP S6232728B2
- Authority
- JP
- Japan
- Prior art keywords
- trapidil
- administration
- shock
- coronary artery
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229960000363 trapidil Drugs 0.000 description 18
- 230000035939 shock Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 206010047302 ventricular tachycardia Diseases 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 229940039009 isoproterenol Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002635 electroconvulsive therapy Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 206010040560 shock Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- -1 mannitrate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLOMZPUITCYLMJ-UHFFFAOYSA-N thiamylal Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O XLOMZPUITCYLMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001166 thiamylal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7309681A JPS57188519A (en) | 1981-05-15 | 1981-05-15 | Remedy for shock |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7309681A JPS57188519A (en) | 1981-05-15 | 1981-05-15 | Remedy for shock |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57188519A JPS57188519A (en) | 1982-11-19 |
| JPS6232728B2 true JPS6232728B2 (de) | 1987-07-16 |
Family
ID=13508456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7309681A Granted JPS57188519A (en) | 1981-05-15 | 1981-05-15 | Remedy for shock |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS57188519A (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210034483A (ko) | 2019-09-20 | 2021-03-30 | 삼성전기주식회사 | 전자 부품 |
-
1981
- 1981-05-15 JP JP7309681A patent/JPS57188519A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210034483A (ko) | 2019-09-20 | 2021-03-30 | 삼성전기주식회사 | 전자 부품 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57188519A (en) | 1982-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Till et al. | Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. | |
| Samarendra et al. | QT prolongation associated with azithromycin/amiodarone combination | |
| Szilvassy et al. | Ventricular overdrive pacing-induced anti-ischemic effect: a conscious rabbit model of preconditioning | |
| Prystowsky et al. | Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. | |
| SAMPSON et al. | The treatment of certain cardiac arrhythmias with potassium salts | |
| CA2168203C (en) | Medicinal for protection from neurological damage | |
| Wayne et al. | The effect of adenosine triphosphate on the electrocardiogram of man and animals | |
| KIKUCHI et al. | Hypotensive action of N-ethoxycarbonyl-3-morpholinosydnonimine, SIN-10 | |
| Barold et al. | Reciprocal beating induced by ventricular pacing | |
| SAGALL et al. | Studies on the action of quinidine in man: I. Measurement of the speed and duration of the effect following oral and intramuscular administration | |
| GB2151136A (en) | Products containing proglumide and their use | |
| Zannad et al. | Hemodynamic and electrophysiologic effects of a new alpha2-adrenoceptor agonist, rilmenidine, for systemic hypertension | |
| Gooden et al. | The magnitude of the bradycardia induced by face immersion in patients convalescing from myocardial infarction | |
| JPS6129927B2 (de) | ||
| Bruyneel et al. | The value of warning arrhythmias in the prediction of ventricular fibrillation within one hour of coronary occlusion. Experimental studies in the baboom | |
| JPS6061527A (ja) | 抗不整脈効力を有する医薬組成物 | |
| Finnegan et al. | Depression of the heart by quinidine and its treatment | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| JPS5827773B2 (ja) | 癌転移抑制剤 | |
| Klainer et al. | A case of short PR interval and prolonged QRS complex with a paroxysm of ventricular tachycardia | |
| KAWAKAMI et al. | Antiarrhythmic effect of aprindine on several types of ventricular arrhythmias | |
| Camm et al. | Intravenous disopyramide phosphate and ventricular overdrive pacing in the termination of paroxysmal ventricular tachycardia | |
| Gmeiner et al. | Metoprolol in the treatment and prophylaxis of paroxysmal reentrant supraventricular tachycardia | |
| Johnson et al. | Cardiovascular effects of brevetoxins in dogs | |
| Mostert et al. | Experimental study of arrhythmias and bronchospasm associated with the use of hexafluorenium |